# ASX release

23 November 2026

## Change of Director's Interest – David Koczkar

In accordance with the Listing Rules, Medibank attaches an Appendix 3Y – Change of Director's Interest Notice for David Koczkar for release to the market.

**This document has been authorised for release by Mei Ramsay, Company Secretary.**

**For further information please contact:**


### For media

Emily Ritchie
Senior Executive, External Affairs
M: +61 429 642 418
E: Emily.Ritchie@medibank.com.au

### For investors/analysts

Colette Campbell
Senior Executive, Investor Relations
M: +61 475 975 770
E: Investor.Relations@medibank.com.au

*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

| |
|---|
| **Name of entity: MEDIBANK PRIVATE LIMITED** |
| **ABN: 47 080 890 259** |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director** | David Koczkar |
| **Date of last notice** | 7 September 2026 |

**Part 1 - Change of director's relevant interests in securities**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or indirect interest** | Direct (Performance Rights pursuant to the Medibank Private Limited Performance Rights Plan (*'Performance Rights Plan'*)) |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | |
| **Date of change** | N/A |
| **No. of securities held prior to change** | 2,051,628 Performance Rights, being:<br>• 490,485 Performance Rights granted under the FY24 Long Term Incentive (*LTI*);<br>• 104,803 Performance Rights granted under the FY24 Deferred Short Term Incentive (*Deferred STI*);<br>• 758,130 Performance Rights granted under the FY25 LTI;<br>• 105,744 Performance Rights granted under the FY25 Deferred STI; and<br>• 592,466 Performance Rights granted under the FY26 LTI. |
| **Class** | Performance Rights |
| **Number acquired** | Nil |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **Number disposed** | Nil |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and estimated valuation | N/A |
| **No. of securities held after change** | 2,051,628 Performance Rights, being:<br>• 490,485 Performance Rights granted under the FY24 LTI;<br>• 104,803 Performance Rights granted under the FY24 Deferred STI;<br>• 758,130 Performance Rights granted under the FY25 LTI;<br>• 105,744 Performance Rights granted under the FY25 Deferred STI; and<br>• 592,466 Performance Rights granted under the FY26 LTI. |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | N/A |

| | |
|---|---|
| **Direct or indirect interest** | Direct and Indirect |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | Indirect interest in Ordinary Shares held via Olive Man Investments Pty Ltd |
| **Date of change** | 20 November 2026 |
| **No. of securities held prior to change** | 2,485,576 Ordinary Shares, being:<br>• 65,073 Ordinary Shares (direct);<br>• 2,420,503 Ordinary Shares (indirect). |
| **Class** | Ordinary Shares |
| **Number acquired** | Nil |
| **Number disposed** | 141,000 Ordinary Shares |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and estimated valuation | 141,000 Ordinary Shares at $5.25 per share |
| **No. of securities held after change** | 2,344,576 Ordinary Shares, being:<br>• 65,073 Ordinary Shares (direct);<br>• 2,279,503 Ordinary Shares (indirect). |

| | |
|---|---|
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | On-market sale of Ordinary Shares to fund tax liability |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

## Part 3 – +Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | No |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |

+ See chapter 19 for defined terms.